Literature DB >> 15383637

The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.

I Feinberg1, D D Schoepp, K-C Hsieh, N Darchia, I G Campbell.   

Abstract

The highly selective metabotropic glutamate (mGlu)2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] completely suppresses rapid eye movement (REM) sleep and strongly depresses theta (6-10 Hz) and high-frequency (10-60 Hz) power in the waking and nonrapid eye movement (NREM) EEG, effects consistent with depressed brain excitation (arousal). We hypothesized the selective mGlu2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] given alone would 1) increase arousal, producing sleep-wake EEG effects opposite those of LY379268, and 2) block/reverse the effects of LY379268 when the drugs are coadministered. Rats with implanted electrodes were injected with 1, 5, or 10 mg/kg LY341495 at hour 5.5 of the dark period. In the coadministration study the rats received the same dose of LY341495 followed 30 min later by 1 mg/kg LY379268. LY341495 alone increased waking by reducing NREM and REM sleep. LY341495 also depressed low-frequency and stimulated high-frequency EEG power. It produced a sharp spike in theta power in waking but not NREM sleep, a striking state-dependent difference in pharmacological response. These changes indicate that blocking mGlu2/3 receptors increases brain arousal. Moreover, they show that mGlu2/3 receptors actively support arousal even in the absence of heightened glutamate excitation. The coadministration experiment demonstrates that LY341495 is selective in vivo since it dose-dependently attenuates or reverses the sleep-wake EEG effects of the highly selective mGlu2/3 receptor agonist LY379268. The capacity of mGlu2/3 receptor agonists and antagonists to alter the sleep wake balance suggests they could be developed to enhance sleep or sustain arousal. Their opposing actions on theta EEG could test the putative role of these oscillations in memory consolidation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383637     DOI: 10.1124/jpet.104.076547

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Effects of microinjections of Group II metabotropic glutamate agents into the amygdala on sleep.

Authors:  Enheng Dong; Laurie L Wellman; Linghui Yang; Larry D Sanford
Journal:  Brain Res       Date:  2012-03-08       Impact factor: 3.252

2.  Transcriptional Profiling of Cholinergic Neurons From Basal Forebrain Identifies Changes in Expression of Genes Between Sleep and Wake.

Authors:  Elena V Nikonova; Jason DA Gilliland; Keith Q Tanis; Alexei A Podtelezhnikov; Alison M Rigby; Raymond J Galante; Eva M Finney; David J Stone; John J Renger; Allan I Pack; Christopher J Winrow
Journal:  Sleep       Date:  2017-06-01       Impact factor: 5.849

3.  Amygdalar glutamatergic neuronal systems play a key role on the hibernating state of hamsters.

Authors:  Raffaella Alò; Ennio Avolio; Antonio Carelli; Rosa Maria Facciolo; Marcello Canonaco
Journal:  BMC Neurosci       Date:  2011-01-20       Impact factor: 3.288

4.  Deletion of Metabotropic Glutamate Receptors 2 and 3 (mGlu2 & mGlu3) in Mice Disrupts Sleep and Wheel-Running Activity, and Increases the Sensitivity of the Circadian System to Light.

Authors:  David Pritchett; Aarti Jagannath; Laurence A Brown; Shu K E Tam; Sibah Hasan; Silvia Gatti; Paul J Harrison; David M Bannerman; Russell G Foster; Stuart N Peirson
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

5.  mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats.

Authors:  Abdallah Ahnaou; Hilde Lavreysen; Gary Tresadern; Jose M Cid; Wilhelmus H Drinkenburg
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

6.  Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression.

Authors:  Christian M Wood; Keith A Wafford; Andrew P McCarthy; Nicola Hewes; Elaine Shanks; David Lodge; Emma S J Robinson
Journal:  Neuropharmacology       Date:  2018-07-11       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.